Connect with us

Health

Voruciclib Alone, Plus Sotorasib or Adagrasib, Shows Preliminary Potency Against KRAS+ Cancers – OncLive

The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant…

Published

on

Article feature image
ADVERTISEMENT

The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant cancers when used in combination with sotorasib (AMG 510) and adagrasib in preclinical models, according to findings presented during Week 1 of the 2021 AACR Virtual Annual Meeting.1,2
The early results showed that voruciclib led to a rapid decrease in the phosphorylation of proteins that promote MYC transcription and quickly decreases…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

New concerns as Indian Covid variant clusters found across England – The Guardian
Article feature image
Denmark eases more Covid restrictions with new ‘corona pass’ – Yahoo News Australia